Oxford Immunotec (OXFD) 8.21 $OXFD Oxford Immunotec

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 8:12 AM

Oxford Immunotec (OXFD) 8.21 $OXFD

Oxford Immunotec Reports Second Quarter 2016 Financial Results
Globe Newswire - 1 hr 11 mins ago
- Second quarter revenue of $19.2 million, increased 34% compared to prior year period
OXFD: 8.21 (+0.17)

Inivata Adds to Board of Directors With Appointment of Peter Wrighton-Smith
PR Newswire - Tue Jul 26, 4:30AM CDT
Inivata, a global clinical cancer genomics company employing the precision of circulating tumour DNA (ctDNA) analysis to improve personalised healthcare in oncology, has appointed Dr Peter Wrighton-Smith to its Board of Directors. Dr Wrighton-Smith brings strategic product development and international commercialisation experience to Inivata's Board along with a broad understanding of the clinical service testing market.
OXFD: 8.21 (+0.17)

Oxford Immunotec Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016
Globe Newswire - Mon Jul 18, 11:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release second quarter 2016 financial results prior to market open on Tuesday, August 2, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 8.21 (+0.17)

Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
Globe Newswire - Thu Jun 23, 3:05PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
OXFD: 8.21 (+0.17)

Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 8.21 (+0.17)

Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 8.21 (+0.17)

Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 8.21 (+0.17)

Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 8.21 (+0.17)

Oxford Immunotec Takes Active Role in Raising Awareness of TB Testing and Prevention during World TB Day
Globe Newswire - Thu Mar 24, 8:00AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the company's commitment to building awareness of TB testing and prevention during World TB Day on March 24, 2016 through its support of educational programs around the world.
OXFD: 8.21 (+0.17)

Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 8.21 (+0.17), LMNX: 21.86 (+0.43)

Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 8.21 (+0.17), LMNX: 21.86 (+0.43)

Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 8.21 (+0.17)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Decision Logic Innovates with Vitals & ShiftFlow Tools

Restaurant Battlefields: The Need for Real-Time Response Running a restaurant is no walk in the park. One slip, and you're dealing with spoiled soup or crabby customers. Decision Logic reckons they've cracked the code to smoother operations with their new tools, Vitals and ShiftFlow. At heart, these products do one thing: put critical data into the hands of managers while...

First Lady Steals NYSE Show, Investors Eye Stakes

Something's Buzzing at the Big Board Walk over to Wall Street on September 23rd, and guess what you get? A lot more than just stock tickers blinking away. First Lady Melania Trump’s stealing the show at the New York Stock Exchange to kick off the inaugural IMPERIA Summit. She’s there to sound the opening bell and lead the charge in a summit that's focused on the...

AdminaHealth's AI Assistant Elevates Billing Solutions

AdminaHealth Unveils AI Data Assistant for Enterprises Amid the hustle and bustle of business operations, AdminaHealth has tossed a digital lifeline into the sea of billing chaos. Enter their AI-powered data assistant, now available to the big players on the Enterprise Tier within the AdminaHealth Billing Suite. This tool isn't just some gizmo for show; it's a genuine...

Epiclay: Game Changer for Sculptors Debuts

Epiclay™ Brings New Energy to Sculpting World Folks, if ever there was a time to break the mold, it’s now, and Ace of Clay’s got us covered with Epiclay™—a fresh take on polymer clay that’s turning heads in the sculpture circuit. Over four long years, Ace of Clay, a brand that's gathered a rather colorful following through captivating sculptures and detailed...

Flux Expands AI Platform to Prove Engineering ROI

Navigating the AI Maze: Flux's New Pathways Ever feel like these engineering platforms speak a language of their own? Flux's latest expansion finally offers a translator that matters. It's all about decoding whether your AI investment is delivering the goods. Engineering leaders now have more than just fluffy metrics; Flux breaks down real code-based evidence to show if...

Youth Mental Health: New Survey Spurs Action

What's the 2025 Survey Telling Us? Numbers hit like a gut punch, don't they? The 2025 National Youth Risk Behavior Survey unveils some hard truths — truths that can't be softer just because we've made headway. We're talking about one in three high schoolers in this country feeling persistently down. That's about 33.3% of them, wrestling with sadness and hopelessness...

Apex Dental's Growth Shines in Inc. 5000 Ranking

Another Year, Another Milestone for Apex Dental Let's talk about steady growth. Apex Dental Partners has made it onto the Inc. 5000 list for the eighth straight year, landing at No. 3,850. Quite a feat, considering this list only features America's fastest-growing private companies. Apex isn't just maintaining its position out of sheer luck. Revenue shot up by 67% over...

BlueCollar Backs SuiteWorld 2026 with Platinum Sponsorship

BlueCollar Cloud Aligns with SuiteWorld 2026 If you thought the construction ERP space was just a dusty office in a backlot, think again. BlueCollar Cloud is strapping on its boots and diving into the heart of SuiteWorld 2026 with a platinum sponsorship. This isn't just a walk in the park—it's a strategic power move, aligning themselves smack-dab in the middle of...

Class Action Lawsuit Targets Lincoln Educational Services

Legal Maneuver Against Lincoln Educational Services Here we go again—another day, another lawsuit. The recent flap with Lincoln Educational Services Corporation (NASDAQ: LINC) is as classic as any market rug pull. Stepping into the spotlight, Wolf Haldenstein Adler Freeman & Herz LLP—a courtroom icon since 1888—has announced a class action lawsuit against Lincoln....

Riverside Theatre Appoints Seasoned CFO for Growth Phase

Change Is Afoot at Riverside Theatre Down in Vero Beach, amid the sun-drenched coziness of Florida’s Treasure Coast, something’s cooking that has nothing to do with sunshine: Riverside Theatre snagged itself a new Chief Financial Officer. As nonprofits go, this one’s not a backyard operation—it’s the largest independent professional theatre in the entire state....